OBJECTIVES: To assess the association between self-reported neuropathic pain severity and the EQ-5D. METHODS: This study used data from baseline responses from 2719 participants to 3 longitudinal internet surveys who: 1) reported ≥3 months of pDPN/PHN; 2) were receiving a prescription/OTC medication to treat pDPN/PHN; and 3) had completed a baseline EQ-5D. Ordered logistic regression models were used to assess the association between EQ-5D items and pain severity, adjusting for age, gender and years since pDPN/PHN diagnosis. Pain severity was assessed using the 11-point pain-intensity numerical rating scale (0=no pain to 10=pain as bad as you can imagine). The likelihood-ratio test was used to test the proportionality of odds assumption. RESULTS: Respondents were 56% female, mean age 55.48 (±10.65) years, had pDPN/PHN duration for 5.1 (±4.7) years, and had mean (median) pain severity of 5.7 (6.0). The proportionality of odds assumption was not rejected (P<0.05). Compared with reference pain severity=0, participants with greater pain severity were more likely to report greater health deficits on the EQ-5D items. All covariates were significantly (P≤0.05) associated with the EQ-5D items except for age on “Mobility” and lower pain severity (1 or 2) on “Mobility” and “Self-care”. As expected, item “Pain/discomfort” demonstrated greater association with pDPN/PHN pain severity. For instance, relative to respondents with pain severity=0, respondents with pain severity=1 and =10 were 2.52 (p=0.026) and 1954.33 (p<0.0001) times more likely to report more severe “pain/discomfort”, respectively. In comparison, respondents with pain severity=10 were 13.05, 13.83, 24.50, and 38.83 times more likely to report more difficulties on “Self-care”, “Anxiety/depression” “Mobility”, and “Usual activities” (p<0.0001), respectively, relative to respondents with pain severity=0. CONCLUSIONS: A strong association exists between self-reported neuropathic pain severity and the EQ-5D. The EQ-5D is sensitive in detecting health disparities among moderate to severe chronic pDPN/PHN patients.